A Phase 2 interventional study of Tirzepatide and Resistance Exercise in Acute Lymphoblastic Leukemia and Obesity, sponsored by St. Jude Children's Research Hospital. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-04.
Sponsored by St. Jude Children's Research Hospital · Phase 2, Interventional, and Treatment
How we know · 3 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital — 15 open to participants now, 25 under way, 1 of them phase 3. Precursor Cell Lymphoblastic Leukemia-Lymphoma · St. Jude Children's Research Hospital.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, this one is the 43rd largest by planned enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2026, is one of 19 in phase 2, reaches primary completion later than 14 of the 24 other live ones, and was the 67th registered.
2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.
Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →15 of the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital are open now, in 1 country. Recruiting first, the newest first:
St. Jude Children's Research Hospital · Sites in United States
St. Jude Children's Research Hospital · Sites in United States
Ages 8+ · Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
Ages up to 21
St. Jude Children's Research Hospital · Sites in United States
Ages 20–50
St. Jude Children's Research Hospital · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 8 · Phase 4 2
First in 1993; this study’s year is marked. 6 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 40 across 1,953 interventional studies indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma.
Median enrollment 42 across the 57 interventional studies, 165 across the 13 observational. Of the 44 that completed or were terminated, 17 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
St. Jude Children's Research Hospital is the lead sponsor of 441 studies on the registry; 103 are open to participants now.
Of its 61 completed or terminated interventional studies of FDA-regulated products, 37 (61%) have results posted.
6 of the studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06747910St. Jude Children's Research HospitalAssessment of Remote Approaches for Identification of Autonomic Dysfunction Among Survivors of Leukemia and Lymphoma | 2026-12 |
| NCT04195347St. Jude Children's Research HospitalStudy of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase | 2027-01 |
| NCT05763290St. Jude Children's Research HospitalChildhood Cancer Survivors' Affective Response to Exercise | 2027-02 |
| NCT06819475St. Jude Children's Research HospitalImaging Skeletal Muscle Mitochondrial OXPHOS Activity In Acute Lymphoblastic Leukemia Survivors | 2027-07 |
| NCT04881240St. Jude Children's Research HospitalStudy of CD19 Allogeneic Memory T-cell Therapy for Relapsed/Refractory CD19+ Leukemia | 2027-07-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 70 studies in Precursor Cell Lymphoblastic Leukemia-Lymphoma by St. Jude Children's Research Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity.
Primary Objective(s):
The study will target a proportion of participants achieving 5% weight loss of 70% and consider fewer than 40% achieving 5% weight loss as unacceptable.
Secondary Objective(s):
Survivors of childhood ALL are at increased risk for obesity and cardiometabolic disease. Tirzepatide is FDA-approved for weight management in adults and results in significant weight loss but may cause lean mass loss. Resistance exercise programs are feasible and effective in this population.
This study evaluates the efficacy of combining Tirzepatide with resistance exercise in adult survivors of ALL treated with chemotherapy only and at least 2 years off therapy.
The primary objective is to estimate the proportion of participants achieving ≥5% weight loss over 28 weeks. Secondary objectives include adherence to the intervention and changes in body composition, cardiometabolic health, and aging biomarkers.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Consistent with the FDA-approval for marketing of Tirzepatide for the treatment of obesity:
Participant has obesity ( > 30kg/m2) or overweight (BMI > 27kg/m2) with ≥1 weight related co-morbidity (hypertension, dyslipidemia, obstructive sleep apnea, cardiovascular disease)
Exclusion Criteria:
Participant is using or has used weight management medication in the past 3 months or had recent significant weight loss > 5kg in the last 3 months Severe renal dysfunction ( \<30 mL/min/1.73 m²)
Note: Use of metformin or any other glucose-lowering medication, whether prescribed for polycystic ovary syndrome or diabetes prevention is not permitted.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This is a 28-week, single-arm, open-label phase II clinical trial evaluating the combination of Tirzepatide and remote, supervised, tailored resistance exercise training to achieve weight loss in adult survivors of childhood acute lymphoblastic leukemia (ALL) living with obesity or overweight with comorbidity. The primary goal is to achieve ≥5% weight loss while preserving lean muscle mass. Interventions: * Tirzepatide: Weekly subcutaneous injections starting at 2.5 mg, titrated every 4 weeks up to 15 mg as tolerated. * Resistance Exercise: Remote, supervised, tailored resistance training 3 times per week for 28 weeks. * Lifestyle Counseling: Every 4 weeks focused on balanced diet and caloric deficit.
Drug: Tirzepatide · Behavioral: Resistance Exercise · Behavioral: Lifestyle Counseling
A once-weekly subcutaneous injection starting at 2.5 mg and dose escalation every 4 weeks up to a maximum of 15 mg, following FDA-approved guidelines. Dose escalation may be paused for exceptional responders.
A remote, supervised, tailored program delivered via a digital platform, with three sessions per week. Supervision is reduced over time (initially 2x/week, then reduced gradually).
Provided every 4 weeks, focusing on balanced diet, caloric deficit, and symptom management.
To evaluate the effectiveness for weight loss of the combined intervention using once weekly Tirzepatide plus remote, supervised, tailored resistance exercise.
The effectiveness will be estimated as the proportion of evaluable participants (those completing both week 0 and 28 visits) who achieve at least 5% weight loss from baseline to week 28.
Time frame: 28 weeks (assessed baseline and Week 28)
To estimate the proportion of participants who adhere to the 28-week combined intervention.
Adherence to Tirzepatide will be defined as receiving at least 70% of prescribed doses. Adherence to resistance exercise will be defined as attending at least 50% of prescribed exercise sessions. Adherence to the combined intervention will be considered if participants complete the study and meet both the Tirzepatide and exercise adherence endpoint.
Time frame: 28 weeks
To estimate the average percentage weight loss from week 0 to 28 for participants completing the combined 28-week intervention.
Weight will be monitored at each visit to determine the total amount of weight loss from week 0 to week 28.
Time frame: 28 weeks
Started Apr 2026 (actual). Primary completion is estimated for Nov 2027, 19 months after the start.
Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 19 months is below that.
Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tirzepatide
Precursor Cell Lymphoblastic Leukemia-Lymphoma →
St. Jude Children's Research Hospital →